MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.
Girvan
Rebecca C
RC
Innate Therapeutics Ltd, PO Box 91806, AMSC, Victoria Street West, Auckland 1142, New Zealand.
Knight
Deborah A
DA
O'Loughlin
Chris J
CJ
Hayman
Colin M
CM
Hermans
Ian F
IF
Webster
Gill A
GA
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage* / Q000302:isolation & purification; D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects / Q000302:isolation & purification; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines; D045142:Cross-Priming; D016207:Cytokines / Q000378:metabolism; D004269:DNA, Bacterial / Q000008:administration & dosage* / Q000302:isolation & purification; D003713:Dendritic Cells / Q000276:immunology; D004705:Endocytosis; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology*; D011425:Propionibacterium acnes / Q000737:chemistry*; D018417:Th1 Cells / Q000276:immunology*; D014611:Vaccination / Q000379:methods
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D004269:DNA, Bacterial; C000605233:MIS416 vaccine; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D010047:Ovalbumin